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The study investigates the cellular expression of kynurenine aminotransferases (KAT I and II) in the rat retina during devel-
opment. At P1 (the day of birth) and P7 (the 7th day after birth), KAT I expression was observed in the inner plexiform layer (IPL),
the ﬁber layer (FL), and in vertically running processes in the ganglion cell layer (GCL) (but not in the cell bodies). At P14 (the 14th
day after birth) a strong KAT I immunoreactivity was observed in M€uller cell endfeet. KAT II was expressed in the IPL, the FL, and
in cells in the GCL at P1 and P7. From P14 on, KAT II expression in the IPL decreased. Double labeling revealed that KAT I was
expressed in M€uller cell endfeet, whilst KAT II both on retinal ganglion cells (RGC) and M€uller cell endfeet.
In conclusion, KAT I and II are present in the rat retina during development. The heterogeneity of the KAT developmental
proﬁles possibly reﬂects a neuromodulatory role in the retinal diﬀerentiation.
 2003 Elsevier Ltd. All rights reserved.
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Kynurenine aminotransferases (KAT I and II) are
pivotal to the synthesis of the tryptophan metabolite
kynurenic acid (KYNA), the only known endogenous
antagonist of glutamate (Perkins & Stone, 1982) and
acetylcholine a7 nicotinic receptors (Hilmas et al., 2001).
Investigations of KYNA synthesis are of particular
interest because of its neuroprotective activity (Andine
et al., 1988; Foster, Vezzani, French, & Schwarcz, 1984).
Importantly, KYNA has been suggested to modulate
glutamate-mediated synaptogenesis and neurotransmis-
sion during brain development (Ceresoli-Borroni &
Schwarcz, 2001). Marked changes of brain KYNA* Corresponding author. Present address: Department of Pathophy-
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doi:10.1016/j.visres.2003.07.007concentrations were found prior to and following birth
(Beal, Swartz, & Isacson, 1992) and during the devel-
opment and aging processes in rodents (Moroni, Russi,
Lombardi, Beni, & Carla, 1988). Since glutamate re-
ceptors are already present at birth and show diﬀerences
in spatial distribution and temporal expression in rat
retinas (Grunder, Kohler, & Guenther, 2000; Grunder,
Kohler, Kaletta, & Guenther, 2000) it is conceivable
that changes of KYNA availability might modulate the
function of excitatory synapses (Carpendo et al., 2001).
It is signiﬁcant that KYNA was identiﬁed and
quantiﬁed in the adult rat retina (Rejdak et al., 2002) in
concentrations in the same range as those measured in
the rat, rabbit and human brain (Moroni et al., 1988;
Turski et al., 1988). Recently, we reported that KYNA
is present in both the vascular rat retina and the avas-
cular chicken retina during development (Rejdak et al.,
2001).
Endogenous KYNA is produced by irreversible
transamination of L-kynurenine by KAT I and II
(Guidetti, Okuno, & Schwarcz, 1997). KAT I has been
2 R. Rejdak et al. / Vision Research 44 (2004) 1–7visibly demonstrated immunohistochemically in the rat
brain (Du et al., 1992; Knyihar-Csillik, Okuno, & Vec-
sei, 1999; Roberts, Du, McCarthy, Okuno, & Schwarcz,
1992), the medulla and the spinal cord (Kapoor, Okuno,
Kido, & Kapoor, 1997) whereas KAT II was ﬁrst
identiﬁed by Northern blot mRNA analysis in the
human brain (Okuno et al., 1990). Immunohistochemi-
cal experiments using KAT I and II antibodies (Okuno,
Nakamura, & Schwarcz, 1991; Okuno, Tsujimoto, Na-
kamura, & Kido, 1993) have shown that both enzymes
are present in the inner retina of the adult rat (Rejdak
et al., 2002). Recently we showed that KAT I enzymatic
activity changes during embryogenesis (Rejdak, Zie-
linska, Shenk, et al., 2003).
Since it is established fact that KYNA is present in
the vascularised rat and avascular chicken retina in high
concentrations in early developmental stages and that its
concentration decreases during aging (Rejdak et al.,
2001), this study was designed to investigate if those
changes of the retinal KYNA synthesis are due to
changes in the cellular expression of KAT I and II in the
rat retina during development.2. Material and methods
All experiments were performed in compliance with
the guidelines of animal care in the European Commu-
nity and the Association for Research in Vision and
Ophthalmology.
2.1. Tissue preparation
Retinas from Brown Norway rats at diﬀerent de-
velopmental stages between the ﬁrst day of life and
the adult stages were used in this study. The day of
birth was designated as postnatal day 1 (P1). Rats were
sacriﬁced with CO2. Eyes were removed, the anterior
segments were dissected, and the eyecups were immer-
sion-ﬁxed for 30 min in 4% (wt./vol) paraformaldehyde
in phosphate buﬀer (PB; 0.1 M, pH 7.4) at 4 C. After
washing in PB, tissues were cryoprotected by immersion
in 30% (wt./vol) sucrose in PB overnight at 4 C. Sam-
ples were embedded in cryomatrix (Leica, Heidelberg,
Germany), cut vertically in 10–12 lm-thick sections
using a cryostat, collected on gelatin-coated slides, air
dried, and stored at )20 C for further use.
2.2. Immunohistochemistry
Endogenous peroxidase was blocked with 3% H2O2
in 40% methanol; subsequently, sections were incubated
for 1 h with 10% normal goat serum (NGS; Sigma,
Munich, Germany) and 0.3% Triton X-100 in phos-
phate-buﬀered saline (PBST) to reduce background
staining. Primary antibodies were diluted in PBSTcontaining 10% NGS, for immunohistochemistry with
antibodies against KAT I and II and incubated over-
night at 4 C. KAT I and II were detected using either
an anti-KAT I polyclonal antibody raised in rabbit
against rat kidney KAT I or anti-human liver KAT II
polyclonal antibody (primary antibodies) (Okuno et al.,
1991, 1993).
Both antibodies were diluted to 1:50 in PBST. After
washing with PBS, the samples were incubated for 1 h
with the biotin-conjugated secondary antibody (dilution
1:200; Vectastain Elite Kit; Vector Laboratories, Bur-
lingame, CA) in PBST with 5% NGS. After rinsing in
PBS, retinal sections were processed with an avidin–
biotin–peroxidase complex (Vectastain Elite Kit; Vector
Laboratories) and stained with diaminobenzidine reac-
tion products. For double labeling immunoﬂuorescence,
the preblocking step and primary antibodies incubation
were performed in 20% NGS plus 2% bovine serum al-
bumin (BSA, Sigma). Secondary antibodies (Molecular
Probes; dilutions were 1:1000) were conjugated either to
Alexa 568 (rabbit) or Alexa 488 (mouse).
A monoclonal antibody directed against glutamine
synthetase was used as a marker for M€uller cells
(Chemicon, dilution 1:500). To label RGC, the ﬂuores-
cent tracer hydroxystilbamidine methanesulfonate
(Fluorogold, Molecular Probes, Eugene, OR) was ap-
plied to each of the superior colliculi by stereotaxic in-
jection 5 days before the rats were sacriﬁed and
processed for immunohistochemistry. Retinal control
sections were processed as described above, with the ﬁrst
antisera omitted.3. Results
3.1. KAT I expression
KAT I immunoreactivity was present from P1 on at
all developmental ages studied, but showed diﬀerent
spatial distribution and temporal expression patterns
(Fig. 1). On P1 and P7, KAT I expression was found
from the border of the neuroblast layer to the vitreal
border, i.e. in the developing IPL, the FL, and in pro-
cesses ascending vertically through the GCL; the cell
bodies of the GCL themselves were free of any staining.
A strong KAT I immunoreactivity was observed in
M€uller cell endfeet and processes surrounding the cells
in the GCL, but, staining did not proceed beyond the
GCL. The entire IPL showed a diﬀuse but pronounced
immunoreaction. No staining was observed in the cells
of the neuroblast layer. At P14 KAT I reached its ﬁnal,
adult distribution. At that time the neuroblast layer had
diﬀerentiated into the layers of the mature retina, and
this pronounced KAT I staining of the IPL was no
longer visible; immunoreactivity was restricted to a
small band of stained ﬁbers at the border between the
Fig. 1. DAB labeling of KAT I in radial sections of the rat retina at diﬀerent developmental stages (P1, P7, P14, P30, P90). The ganglion cell layer is
oriented downwards. KAT I is expressed from P0 on at all developmental ages analyzed. At P1 and P7, KAT I is present from the border of the NL
to the vitreal border, i.e. in the developing IPL, the GCL and the FL. Somata in the GCL were free of labeling. Strong KAT I immunoreactivity was
observed in M€uller cell endfeet (black arrowhead) and their processes, but not beyond the GCL. At P14, KAT I reaches its ﬁnal adult distribution,
which can be also observed in the adult stages. KAT I staining is restricted to a small band of stained ﬁbres at the border between the GCL and the
IPL, while the IPL itself is no longer labeled. There is no cellular staining in neurons of the inner or outer retina. NBL, neuroblastic layer; ONL, outer
nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar¼ 20 lm.
Fig. 2. (A) Fluorescence labeling of KAT I in radial sections of the adult rat retina. Triangles mark M€uller cell endfeet, arrows mark ascending
processes in the IPL. (B) Positive immunoreaction of glutamine synthetase (triangles and arrows are pointing to the same structures as in (A). (C)
Immunostaining in A (red) and B (green) was merged; yellow color indicates the co-localization of both antibodies in the endfeet of M€uller cells; this
stops at the border between the IPL and the RGC layer (white arrows and white triangles). There is no KAT I staining in the distal parts of M€uller
cells. ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale
bar¼ 20 lm.
Fig. 3. (A) Fluorescence labeling of KAT I (white triangles) in radial sections of the adult rat retina; (B) retrogradely labeled RGC (white arrows);
(C) merged pictures of (A) and (B) showing that KAT I immunoreactivity is clearly separated from the RGC. Scale bar¼ 20 lm.
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served in M€uller cell endfeet and their processes but did
not extend beyond the GCL. There was no cellular stain-
ing in the neurons of the inner or outer retina (Fig. 1).
Fig. 4. DAB labeling of KAT II in radial sections of the rat retina at diﬀerent developmental stages (P1, P7, P14, P30, P90). The ganglion cell layer is
oriented downwards. KAT II was expressed from P1 on at all developmental ages studied. At P1 and P7 there was labeling of cells in the IPL, the
GCL and the FL. Entire cells in RGC layer are uniformly stained (white arrows). During aging, a continuous decrease of KAT II expression was
observed. At P90, the most intense labeling was present at the bottom of the cells where the nerve ﬁbres leave the cell (black arrow). No staining was
visible in either the IPL or the outer retina. Scale bar¼ 20 lm. NBL, neuroblastic layer; ONL, outer nuclear layer; OPL, outer plexiform layer; INL,
inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar¼ 20 lm.
Fig. 5. (A) Fluorescence labeling of KAT II (white arrows) in radial sections of the adult rat retina. (B) Fluorescence labeling of glutamine synthetase
(white triangles). (C) Merged immunostaining in A (red) and B (green) showing localization of KAT II in the endfeet of M€uller cells (white triangles)
and cell bodies in the GCL (white arrows). ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform
layer; GCL, ganglion cell layer. Scale bar¼ 20 lm.
Fig. 6. (A) Fluorescence labeling of KAT II (white triangles) in radial sections of the adult rat retina. (B) Retrogradely labeled RGC (white arrows).
(C) Double labeling showing the cellular expression of KAT II both on M€uller cell endfeet (white triangles) and in the cytoplasm of RGC (white
arrows). Scale bar¼ 20 lm.
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tase antibody in adult rat retina demonstrated the ex-
pression of KAT I in the endfeet of M€uller cells. We
observed clear double labeling in the endfeet; this
stopped at the border between IPL and RGC layer.
There was no KAT I staining in the distal parts of
M€uller cells (Fig. 2).
Staining of KAT I after retrograde labeling of RGC
showed that the cellular expression of KAT I was re-
stricted to M€uller cell endfeet. It was clearly separated
from the RGC. Additionally, KAT I was found only in
barely detectable amounts in parts of M€uller cells distal
to IPL. The trunks of M€uller cells were also stained.
There was a faint staining in the border between the
RGC and the IPL. KAT I staining seemed to surround
cells in the GCL, forming ring-like structures (Fig. 3).3.2. KAT II expression
KAT II was expressed from P1 on at all develop-
mental ages studied and showed diﬀerent patterns of
spatial distribution and temporal expression (Fig. 4).
Application of the antibody against KAT II in early
postnatal stages P1 and P7 resulted in strong labeling of
cells in the IPL, RGC and nerve ﬁbre layer. Entire cells
in the GCL were uniformly stained. During aging, KAT
II expression decreased continuously. At P90, the most
intense labeling was present at the vitreal pole of the
somata in the GCL where the nerve ﬁbres leave the cell.
No staining was observed in either the IPL or the outer
retina (Fig. 4).
Additionally, double labeling with KAT II antibody
and glutamine synthetase antibody also showed KAT II
expression in the M€uller cell endfeet in adult rat retina.
(Fig. 5).
Staining of KAT II after retrograde labeling of RGC
showed that cellular expression of KAT II was present
both on the RGC and in M€uller cell endfeet (Fig. 6).
No staining was observed in either of the controls.4. Discussion
The study described here shows that both KAT I and
II are present in the rat retina during diﬀerentiation, and
that the two enzymes display diﬀerent patterns of spatial
distribution and temporal expression. The pronounced
expression of both enzymes in early developmental
stages generally paralleled our previous results showing
that KYNA, the product of both enzymes, was present
in both vascularised rat and avascular chicken retinas
during development. In rats, the retinal KYNA con-
centration peaked at birth and decreased markedly
during the ﬁrst 2 weeks of life. A similar time course of
KYNA content was observed in chicken retinas (Rejdak
et al., 2001). A high level of expression of KAT I and IIin the retina occurs almost exclusively within the ﬁrst
two postnatal weeks and may be related to processes of
synapse formation in the retina. It may also play an
important neuromodulatory role in the retina during
development. At the time of eye opening, about P15–
P17, the expression patterns of KAT I and II are already
very similar to those observed in adult retinas.
Studies of age-related changes of KATs activity in the
rat brain demonstrate a marked heterogeneity of enzy-
matic changes between regions. A signiﬁcant increase of
KAT activity in the cortex, the hippocampus and the
striatum between the ages of 3 and 24 months was ob-
served, while in the thalamus and the cerebellum chan-
ges were much less pronounced in adult rats, and a
decrease was found in old animals (Gramsbergen, Sch-
midt, Turski, & Schwarcz, 1992). Results of the present
study seem to indicate that age-related changes of KATs
expression are speciﬁc for brain structures.
It has been suggested that changes of KYNA avail-
ability may modulate the function of excitatory synapses
(Carpendo et al., 2001). The sensitivity of NMDA re-
ceptors undergoes discrete changes during diﬀerentia-
tion, and regional diﬀerences exist with regard to the
properties of NMDA receptors in both the developing
and the adult brain (McDonald & Johnston, 1990).
Since glutamate receptors, which are preferential targets
of KYNA, are already present at birth and show dif-
ferences in spatial distribution and temporal expression
in the rat retina (Grunder, Kohler, & Guenther, 2000;
Grunder, Kohler, Kaletta, et al., 2000) developmental
changes of KATs and KYNA content may play a role in
glutamate-mediated neurotransmission during diﬀeren-
tiation.
It was recently documented that excitatory amino acid
antagonists can trigger apoptosis in the developing
mammalian brain (Olney et al., 2002) and that KAT I
plays a role in the regulation of programmed cell death
(Csillik, Okuno, Csillik, Knyihar, & Vecsei, 2002). In
light of this, it is conceivable that KAT and KYNA may
control apoptosis in the retina during early development.
The decrease of cellular expression of both KATs
found in our study during postnatal life may also be ex-
plained by a signiﬁcant increase in the total rat reti-
nal content of glutamate during the postnatal period,
synchronous with the generation and maturation of
glutamatergic cells (Haberecht & Redburn, 1996). Data
exist showing that glutamate diminishesKYNA synthesis
in brain slices, and a regulatory inﬂuence on endogenous
KYNA concentration has been suggested (Urbanska,
Chmielewski, Kocki, & Turski, 2000). Also, evidence is
accumulating that cerebral KYNA synthesis is excep-
tionally amenable to modulation by dopaminergic
mechanisms during the early postnatal period (Schwarcz,
Poeggeler, Rassoulpour, Ceresoli-Borroni, & Hodgkins,
1998). Whether dopamine regulates the expression of
KATs in the developing retina remains to be determined.
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I is preferentially expressed in M€uller cell endfeet, while
KAT II is localized in both M€uller cell endfeet and in
retinal ganglion cells (RGC). These ﬁndings are in
agreement with our previous results showing that in the
chicken retina KAT I is expressed in M€uller cell endfeet
(Rejdak, Zielinska, Shenk, et al., 2003). KAT II, which
in contrast to KAT I has a pH optimum in the physi-
ological range (Okuno et al., 1990), is responsible for
most KYNA formation under physiologic conditions
(Guidetti et al., 1997). In the rat hippocampus KAT
immunoreactivity was found mainly in glial cells (Du
et al., 1992) while in the striatum it was observed in both
glial cells and neurons (Roberts et al., 1992). Kapoor
et al. (1997) reported predominantly neuronal KAT lo-
calization in the ventral medulla, the nucleus ambiguus,
the nucleus of the solitary tract, and the intramediolat-
eral cell column of the spinal cord. They also found that
KAT staining appeared to be diﬀuse in astrocytes but
punctate in neurons (Kapoor et al., 1997). This pattern
was similar to that observed in other studies (Okuno
et al., 1991; Du et al., 1992). In contrast, in our study
both M€uller cell endfeet and the cytoplasm of the cells in
the ganglion cell layer were uniformly stained.
It has been suggested that a deﬁciency of KYNA
synthesis is causally related to the pathology of excito-
toxic brain diseases (Schwarcz et al., 1998). Recently, we
reported alterations of KYNA content in the retina in
response to NMDA-induced RGC damage (Rejdak,
Zarnowski, Turski, et al., 2003). Importantly, it has
been found that exposure to the mitochondrial toxins
induces depletion of KAT I cellular expression in the rat
brain. The authors suggested that a decrease of KAT
expression in the brain may directly contribute to
mechanisms of neuronal degeneration (Csillik et al.,
2002; Knyihar-Csillik et al., 1999).
Further studies on the role of KAT I and II in gluta-
mate transmission using pharmacological modulation of
KYNA synthesis or knockout mice models (developed in
the future) are recommended. Possibly the KAT I and II
might be diﬀerently expressed in the various retinal de-
generation models and the time course of their neuro-
modulatory eﬀects can be followed in such models.5. Conclusion
KAT I and II were found in the inner retina. Ex-
pression of KAT I was restricted to M€uller cell endfeet,
while KAT II immunoreactivity was found in both
M€uller cell endfeet and the RGC. Since the high cellular
expression of KAT I and II occur almost exclusively
within the ﬁrst two postnatal weeks, we suggest that
KAT is related to the process of synapse formation in
the retina and may play an important neuromodulatory
role in the retina during development.Acknowledgements
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